Top 20 Immunology Drugs Market Analysis And Segment Forecasts To 2030
- Published: Apr, 2025
- Report ID: GVR-MT-100293
- Format: PDF/Excel databook
- No. of Pages/Datapoints: 150
- Report Coverage: 2024 - 2030
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Research Methodology
1.3. List of Secondary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Top 20 Immunology Drugs Market: Product Business Analysis
3.1. Product Market Share, 2024 & 2030
3.2. Product Segment Dashboard
3.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
3.3.1. Skyrizi
3.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.1.2. Impact of Generics/Biosimilars
3.3.1.3. Patent Expiry Analysis
3.3.1.4. Pricing and Reimbursement Scenario
3.3.1.5. Indication Approved
3.3.1.6. Competitive Scenario
3.3.2. Stelara
3.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.2.2. Impact of Generics/Biosimilars
3.3.2.3. Patent Expiry Analysis
3.3.2.4. Pricing and Reimbursement Scenario
3.3.2.5. Indication Approved
3.3.2.6. Competitive Scenario
3.3.3. Humira
3.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.3.2. Impact of Generics/Biosimilars
3.3.3.3. Patent Expiry Analysis
3.3.3.4. Pricing and Reimbursement Scenario
3.3.3.5. Indication Approved
3.3.3.6. Competitive Scenario
3.3.4. Cosentyx
3.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.4.2. Impact of Generics/Biosimilars
3.3.4.3. Patent Expiry Analysis
3.3.4.4. Pricing and Reimbursement Scenario
3.3.4.5. Indication Approved
3.3.4.6. Competitive Scenario
3.3.5. Entyvio
3.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.5.2. Impact of Generics/Biosimilars
3.3.5.3. Patent Expiry Analysis
3.3.5.4. Pricing and Reimbursement Scenario
3.3.5.5. Indication Approved
3.3.5.6. Competitive Scenario
3.3.6. Rinvoq
3.3.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.6.2. Impact of Generics/Biosimilars
3.3.6.3. Patent Expiry Analysis
3.3.6.4. Pricing and Reimbursement Scenario
3.3.6.5. Indication Approved
3.3.6.6. Competitive Scenario
3.3.7. Orencia
3.3.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.7.2. Impact of Generics/Biosimilars
3.3.7.3. Patent Expiry Analysis
3.3.7.4. Pricing and Reimbursement Scenario
3.3.7.5. Indication Approved
3.3.7.6. Competitive Scenario
3.3.8. Tremfya
3.3.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.8.2. Impact of Generics/Biosimilars
3.3.8.3. Patent Expiry Analysis
3.3.8.4. Pricing and Reimbursement Scenario
3.3.8.5. Indication Approved
3.3.8.6. Competitive Scenario
3.3.9. Enbrel
3.3.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.9.2. Impact of Generics/Biosimilars
3.3.9.3. Patent Expiry Analysis
3.3.9.4. Pricing and Reimbursement Scenario
3.3.9.5. Indication Approved
3.3.9.6. Competitive Scenario
3.3.10. Taltz
3.3.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.10.2. Impact of Generics/Biosimilars
3.3.10.3. Patent Expiry Analysis
3.3.10.4. Pricing and Reimbursement Scenario
3.3.10.5. Indication Approved
3.3.10.6. Competitive Scenario
3.3.11. Actemra
3.3.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.11.2. Impact of Generics/Biosimilars
3.3.11.3. Patent Expiry Analysis
3.3.11.4. Pricing and Reimbursement Scenario
3.3.11.5. Indication Approved
3.3.11.6. Competitive Scenario
3.3.12. Cimzia
3.3.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.12.2. Impact of Generics/Biosimilars
3.3.12.3. Patent Expiry Analysis
3.3.12.4. Pricing and Reimbursement Scenario
3.3.12.5. Indication Approved
3.3.12.6. Competitive Scenario
3.3.13. Simponi
3.3.13.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.13.2. Impact of Generics/Biosimilars
3.3.13.3. Patent Expiry Analysis
3.3.13.4. Pricing and Reimbursement Scenario
3.3.13.5. Indication Approved
3.3.13.6. Competitive Scenario
3.3.14. Otezla
3.3.14.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.14.2. Impact of Generics/Biosimilars
3.3.14.3. Patent Expiry Analysis
3.3.14.4. Pricing and Reimbursement Scenario
3.3.14.5. Indication Approved
3.3.14.6. Competitive Scenario
3.3.15. TYSABRI
3.3.15.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.15.2. Impact of Generics/Biosimilars
3.3.15.3. Patent Expiry Analysis
3.3.15.4. Pricing and Reimbursement Scenario
3.3.15.5. Indication Approved
3.3.15.6. Competitive Scenario
3.3.16. Remicade
3.3.16.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.16.2. Impact of Generics/Biosimilars
3.3.16.3. Patent Expiry Analysis
3.3.16.4. Pricing and Reimbursement Scenario
3.3.16.5. Indication Approved
3.3.16.6. Competitive Scenario
3.3.17. Xeljanz
3.3.17.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.17.2. Impact of Generics/Biosimilars
3.3.17.3. Patent Expiry Analysis
3.3.17.4. Pricing and Reimbursement Scenario
3.3.17.5. Indication Approved
3.3.17.6. Competitive Scenario
3.3.18. Ilumya
3.3.18.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.18.2. Impact of Generics/Biosimilars
3.3.18.3. Patent Expiry Analysis
3.3.18.4. Pricing and Reimbursement Scenario
3.3.18.5. Indication Approved
3.3.18.6. Competitive Scenario
3.3.19. Kinaret
3.3.19.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.19.2. Competitive Scenario
3.3.19.3. Impact of Generics/Biosimilars
3.3.19.4. Patent Expiry Analysis
3.3.19.5. Pricing and Reimbursement Scenario
3.3.19.6. Indication Approved
3.3.19.7. Competitive Scenario
3.3.20. Dupixent
3.3.20.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.20.2. Impact of Generics/Biosimilars
3.3.20.3. Patent Expiry Analysis
3.3.20.4. Pricing and Reimbursement Scenario
3.3.20.5. Indication Approved
3.3.20.6. Competitive Scenario
Chapter 4. Top 20 Immunology Drugs Market: Route of Administration Business Analysis
4.1. Route of Administration Market Share, 2024 & 2030
4.2. Route of Administration Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
4.4. Topical
4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Injectable
4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Oral
4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Top 20 Immunology Drugs Market: Regional Estimates & Trend Analysis
5.1. Regional Market Share Analysis, 2024 & 2030
5.2. Regional Market Dashboard
5.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
5.4. North America
5.4.1. North America Top 20 Immunology Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
5.4.2. U.S.
5.4.2.1. U.S. Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.3. Canada
5.4.3.1. Canada Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.4. Mexico
5.4.4.1. Mexico Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Europe
5.5.1. Europe Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.2. UK
5.5.2.1. Uk Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.3. Germany
5.5.3.1. Germany Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.4. France
5.5.4.1. France Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.5. Italy
5.5.5.1. Italy Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.6. Spain
5.5.6.1. Spain Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.7. Denmark
5.5.7.1. Denmark Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.8. Sweden
5.5.8.1. Sweden Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.9. Norway
5.5.9.1. Norway Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Asia Pacific
5.6.1. Asia Pacific Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6.2. Japan
5.6.2.1. Japan Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6.3. China
5.6.3.1. China Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6.4. India
5.6.4.1. India Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6.5. Australia
5.6.5.1. Australia Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6.6. South Korea
5.6.6.1. South Korea Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6.7. Thailand
5.6.7.1. Thailand Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Latin America
5.7.1. Latin America Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7.2. Brazil
5.7.2.1. Japan Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7.3. Argentina
5.7.3.1. China Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. Middle East and Africa
5.8.1. Middle East and Africa Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8.2. South Africa
5.8.2.1. South Africa Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8.3. Saudi Arabia
5.8.3.1. Saudi Arabia Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8.4. UAE
5.8.4.1. UAE Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8.5. Kuwait
5.8.5.1. Kuwait Top 20 Immunology Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global Top 20 Immunology Drugs by Region, 2018 - 2030 (USD Million)
Table 4 Global Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 5 Global Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 6 Global Top 20 Immunology Drugs by Region, 2018 - 2030 (USD Million)
Table 7 North America Top 20 Immunology Drugs by Country, 2018 - 2030 (USD Million)
Table 8 North America Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 9 North America Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 10 U.S. Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 11 U.S. Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 12 Canada Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 13 Canada Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 14 Mexico Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 15 Mexico Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 16 Europe Top 20 Immunology Drugs by Country, 2018 - 2030 (USD Million)
Table 17 Europe Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 18 Europe Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 19 UK Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 20 UK Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 21 Germany Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 22 Germany Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 23 France Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 24 France Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 25 Italy Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 26 Italy Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 27 Spain Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 28 Spain Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 29 Norway Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 30 Norway Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 31 Sweden Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 32 Sweden Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 33 Denmark Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 34 Denmark Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 35 Asia-Pacific Top 20 Immunology Drugs by Country, 2018 - 2030 (USD Million)
Table 36 Asia-Pacific Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 37 Asia-Pacific Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 38 Japan Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 39 Japan Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 40 China Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 41 China Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 42 India Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 43 India Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 44 Australia Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 45 Australia Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 46 South Korea Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 47 South Korea Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 48 Thailand Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 49 Thailand Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 50 Latin America Top 20 Immunology Drugs by Country, 2018 - 2030 (USD Million)
Table 51 Latin America Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 52 Latin America Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 53 Brazil Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 54 Brazil Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 55 Argentina Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 56 Argentina Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 57 Middle East & Africa Top 20 Immunology Drugs by Country, 2018 - 2030 (USD Million)
Table 58 Middle East & Africa Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 59 Middle East & Africa Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 60 Saudi Arabia Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 61 Saudi Arabia Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 62 UAE Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 63 UAE Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 64 Kuwait Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 65 Kuwait Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 66 South Africa Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 67 South Africa Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
Table 68 Rest of Middle East & Africa Top 20 Immunology Drugs by Product, 2018 - 2030 (USD Million)
Table 69 Rest of Middle East & Africa Top 20 Immunology Drugs by Route of Administration, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Top 20 immunology drugs: market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 Market formulation & validation
Fig. 7 Market snapshot
Fig. 8 Application outlook (USD Million)
Fig. 9 Competitive landscape snapshot
Fig. 10 Market dynamics
Fig. 11 Porter’s five forces analysis
Fig. 12 PESTLE analysis
Fig. 13 Top 20 immunology drugs market: Product outlook and key takeaways
Fig. 14 Top 20 immunology drugs market: Product movement analysis
Fig. 15 Skyrizi market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 16 Stelara market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 17 Humira market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 18 Cosentyx market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Entyvio market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Rinvoq market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Tremfya market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Enbrel market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Taltz market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Actemra market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Cimzia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Simponi market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Otezla market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 TYSABRI market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Remicade market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Xeljanz market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Ilumya market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Kinaret market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Dupixent market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Top 20 immunology drugs market: Route of administration outlook and key takeaways
Fig. 35 Top 20 immunology drugs market: Route of administration movement analysis
Fig. 36 Topical market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Oral market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Top 20 immunology drugs market revenue, by region, 2024 & 2030 (USD Billion)
Fig. 40 Regional marketplace: Key takeaways
Fig. 41 North America top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 42 Key country dynamics: North America
Fig. 43 U.S. top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 44 Canada top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 45 Mexico top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 46 Europe top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 47 Key country dynamics: Europe
Fig. 48 UK top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 49 Germany top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 50 France top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 51 Italy top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 52 Spain top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 53 Norway top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 54 Sweden top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 55 Denmark top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 56 Asia-Pacific top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 57 Key country dynamics: Asia-Pacific
Fig. 58 Japan top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 59 China top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 60 India top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 61 Australia top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 62 South Korea top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 63 Thailand top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 64 Rest of Asia-Pacific top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 65 Latin America top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 66 Key country dynamics: Latin America
Fig. 67 Brazil top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 68 Argentina top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 69 Rest of Latin America top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 70 Middle East & Africa (MEA) top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 71 Key country dynamics: MEA
Fig. 72 Saudi Arabia top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 73 UAE top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 74 Kuwait top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 75 South Africa top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 76 Rest of MEA top 20 immunology drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 77 Company categorization
Fig. 78 Strategy mapping
Fig. 79 Company market position analysis
Fig. 80 Competitive landscape assessment
Fig. 81 Strategic framework analysis
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.